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Abstract Use of adaptive immune receptor repertoire sequencing (AIRR-seq) has become
widespread, providing new insights into the immune system with potential broad clinical and
diagnostic applications. However, like many high-throughput technologies, it comes with several
problems, and the AIRR Community was established to understand and help solve them. We, the
AIRR Community’s Biological Resources Working Group, have surveyed scientists about the need
for standards and controls in generating and annotating AIRR-seq data. Here, we review the
current status of AIRR-seq, provide the results of our survey, and based on them, offer
recommendations for developing AIRR-seq standards and controls, including future work.
Introduction
Immunoglobulin chains (IG) and T-cell receptor chains (TR) are generated by DNA recombination, a
process of somatic rearrangement of variable (V), diversity (D), and joining (J) genes
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(Tonegawa, 1983). The diversity of the resulting rearranged genes (referred as V-J and V-D-J) is
very high, due to not only the combination of different germline V, D, and J genes, but also to the
deletion and addition of templated (P) nucleotides and the addition of non-templated (N) nucleoti-
des at the junctions between the rearranged genes, and somatic hypermutation of expressed IG
(Papavasiliou and Schatz, 2002; Lefranc and Lefranc, 2020). The total number of potential
expressed rearranged IG and TR sequences in an individual is referred to as the adaptive immune
receptor repertoire (AIRR). The adaptive immune repertoire is very diverse in a healthy individual,
with the theoretically possible number of clonotypes reaching more than 1019 different TR
(Bradley and Thomas, 2019) and 1011 IG (Glanville et al., 2009), far exceeds the number of B and
T cells in a given individual (Davis and Bjorkman, 1988; Freeman et al., 2009; Elhanati et al.,
2015). Thanks to next-generation sequencing (NGS), the AIRR can be sampled with sufficient depth
for some of its complexity to be studied (Weinstein et al., 2009; Six et al., 2013). AIRR sequencing
(AIRR-seq) provides insights into the immune status of an individual at steady-state or in altered con-
ditions such as malignancy, autoimmune disease, immunodeficiency, infectious disease, or vaccina-
tion, and allows comparison of B- and T-cell populations between individuals and time points
(Benichou et al., 2012; Kirsch et al., 2015; Dziubianau et al., 2013; Hou et al., 2016;
Ghraichy et al., 2018). AIRR-seq permits the description and quantification of global diversity and
characteristics of AIRR, the identification of clonal expansions, the tracking of particular clonotypes,
and the prediction of their specificities (Miho et al., 2018; Zvyagin et al., 2020; Sidhom et al.,
2018; Glanville et al., 2017; Huang et al., 2020; Jokinen et al., 2021; Akbar et al., 2021;
Hayashi et al., 2021) as well as the antibody selection through phage display (Rouet et al., 2018;
Ravn et al., 2013), thereby providing opportunities for new biomarker identification (Gittel-
man, 2021; Dines, 2020), therapeutic antibody discovery (Akbar et al., 2021; Richardson et al.,
2021), CAR-T cell bioengineering (Sheih et al., 2020), vaccine development, cancer diagnostics and
treatment (Linette et al., 2019; Zhang et al., 2018; Lu et al., 2018), including neoantigen discovery
(Chiou et al., 2021; Richters et al., 2019) and immune intervention monitoring in diverse patholo-
gies, such as stem cell transplantation (Robinson, 2015; Fink, 2019; Jiang et al., 2019;
Jacobsen et al., 2017; Theil, 2017; Link-Rachner et al., 2019; Rubelt et al., 2017; Parola et al.,
2018; Georgiou et al., 2014; Arnaout et al., 2021; Anand et al., 2021).
NGS-based approaches and methods have multiplied, now including high-throughput bulk
sequencing of IG or TR starting from genomic DNA (gDNA) or mRNA (as cDNA), which typically pro-
vides information on one receptor chain only, and more recently to the sequencing of the two IG or
TR chains expressed in a single cell, which provides information on the antigen-specific receptor.
These approaches are increasingly applied, mostly to human AIRRs, but also to study AIRRs from
other organisms (Chaudhary and Wesemann, 2018; Minervina et al., 2019). Molecular protocols to
amplify IG or TR chains typically rely on Polymerase Chain Reaction (PCR), such as multiplex-PCR or
RACE-PCR (Robins et al., 2009; Wang et al., 2010; DeKosky et al., 2013; Eugster et al., 2013;
Heather et al., 2015; Mamedov et al., 2013).
To obtain reliable and comparable AIRR-seq data, the methods for performing AIRR-seq need to
fulfill a number of requirements. First, the data generated by AIRR-seq must reflect the composition
and diversity of the ‘real cellular repertoire.’ The cell subset(s), the cell sample size, and the sequenc-
ing depth used in an AIRR-seq experiment all influence the downstream data and should therefore
be carefully adapted to the experimental question (Rosenfeld et al., 2018). PCR amplification of
AIRR-seq libraries can introduce bias by preferentially targeting certain genes, by missing certain
alleles (in the case of multiplex PCR with primers anchored in the V or J genes), and by overamplify-
ing targets of certain genes and length (in multiplex PCR and RACE-PCR) (Calis and Rosenberg,
2014; Alamyar et al., 2012; Gadala-Maria et al., 2015; Primi et al., 1986; Barennes et al., 2021).
All these parameters will influence how accurately AIRR profiling reflects the true abundance and
diversity of clones in the immune repertoire. Second, AIRR V and J genes (and constant (C) genes
for IG) must be identified in an unambiguous and unbiased manner as knowledge of the comple-
mentarity determining region 3 (CDR3; the site of V, (D), and J recombination in an IG or TR, and
hence its greatest sequence diversity), but also of the CDR1 and CDR2 (and that of the C gene in IG)
is critical to assess the physicochemical constraints that define specificity, affinity, and function of the
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TR or the IG (Li et al., 2013; Rossjohn et al., 2015). Third, AIRR-seq data should be as free from
sequencing error as possible. The CDR3, key for assigning a sequence to a clonotype, is by definition
unknown, and in the case of IG sequences it is important to be able to distinguish bona fide somatic
hypermutation from artifactual mutations introduced by PCR or by sequencing errors all along the
rearranged molecule, as the latter can generate falsely elevated inter- and intra-clonal variation. Fur-
ther complicating the matter is the fact that the germline V genes from the same subgroup (e.g.,
IGHV4-31 vs. IGHV4-30-4 for IG) and V alleles or polymorphic variants of a given gene (e.
g., TRAV14/DV4 for TR) may have very few nucleotide differences (Lefranc, 2014; Lefranc and
Lefranc, 2001). Therefore, distinguishing errors from true biological variants can be a major chal-
lenge. Finally, samples for AIRR-seq should be free from cross-sample contamination, to which AIRR-
seq experiments are prone as multiple samples are often processed in parallel and sequenced on a
single lane of a sequencing run.
In the past decade, multiple molecular biology protocols and approaches have been developed
by academic and industrial investigators, rendering comparisons among studies difficult. Moreover,
experimental and analytical protocols are highly complex and therefore prone to intra- and inter-
experimental variability (Barennes et al., 2021; Liu et al., 2016; Rosati et al., 2017; Bashford-
Rogers et al., 2014). AIRR-seq can be performed either on gDNA or cDNA from multiple T/B cell
populations (bulk sequencing) or on individual cells (single-cell sequencing). The starting material
and sequencing method used depend on the application, as each has advantages and disadvantages
(Table 1). The availability of commercial kits can be helpful, since they are produced following stand-
ards and rigorous quality control, thus offering standardized reagents and protocols across laborato-
ries. Currently, available commercial kits include gDNA-based methods (e.g., Adaptive
Biotechnologies, iRepertoire) as well as mRNA-based methods that use cDNA (e.g., Illumina, Takara
Bio, iRepertoire) for bulk sequencing. Mainly mRNA-based commercial methods (e.g., 10X Geno-
mics, Takara Bio, HiFiBio) are used for single-cell analysis, which can provide sequences for full
receptors or antibodies. This is an important consideration as the determination of the isotype for IG
requires a full or partial sequence of the constant region. Single-cell approaches are further helping
in the detection of clonotypes because they provide both paired chains and potentially allow full-
length cDNA sequencing (Stubbington et al., 2017). The fidelity of sequence is an additional factor
to consider. Unique molecular identifiers (UMI) consisting of random stretches of 8–12 nucleotides
are incorporated into oligonucleotides that are used to generate cDNA from mRNA, such that statis-
tically each cDNA molecule contains a unique sequence. Analysis of sequences that share the same
UMI is used to generate a consensus sequence, greatly reducing sequencing errors (Shugay et al.,
2014). In contrast, multiplex PCR approaches can be associated with artifacts arising from primer
competition or off-target primer binding. Although this favors RACE-PCR when considering mRNA-
based methods, gDNA-based multiplex PCR may offer higher fidelity since it does not rely on
reverse transcription (reverse transcriptase enzymes have higher error rates than DNA polymerases
[Ellefson et al., 2016; Holland et al., 1982]). Finally, cost may influence the choice of a particular
protocol. There are many factors that contribute to the cost of AIRR-seq data generation. For exam-
ple, the cost of sequencing, the sequencing depth, and the number of cells analyzed per sample are
variable; also, the choice between commercial kits and ‘homebrew’ methods will influence costs. In
general, gDNA analysis is the most cost-effective, because it requires the lowest sequencing depth
with the largest representation of cells per sample, whereas single-cell analysis is on the opposite
end of the scale, with bulk cDNA sequencing in the middle.
Several considerations should be taken into account when designing and planning an AIRR-seq
experiment. In addition to the large number of different methods and protocols, other factors
including budgetary constraints, timelines, sample types, and processing are also important. Given
the diversity of AIRR-seq workflows, comparisons between different data sets are challenging or
even impossible. Standards and controls are needed for optimal AIRR-seq data harmonization, inter-
pretation, and sharing (Rubelt et al., 2017; Breden et al., 2017; Vander Heiden et al., 2018). This
need led to the formation in 2015 of a grassroots community of scientists and other interested par-
ties, known as the AIRR Community (https://www.antibodysociety.org/the-airr-community/). The
objective of the Biological Resources Working Group (WG) within the AIRR Community is to coordi-
nate the assessment and development of AIRR-seq controls, ultimately providing the scientific com-
munity with controls and standards for the generation, harmonization, and rigorous comparison and
interpretation of AIRR-seq data. In order to recommend biological standards that are needed and to
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Table 1. Current AIRR-seq methods and their typical use(s).
Bulk gDNA, bulk cDNA, and single-cell cDNA-based sequencing methods are compared with respect to their general features, uses,













Cell number 102–106 102–106 102–103
Sample throughput Low-high Low-moderate Low
Length of receptor sequences 100–600 bp 150–600 bp 700–800 bp
Availability of commercial kits and service providers ++ +++ +
Uses Gene usage ++ ++ +
CDR3 length and properties ++ ++ +
Somatic hypermutation (for IG) ++ ++ +
Repertoire diversity ++ ++ +/-
Clonal expansion +++ ++ +
Clonal evolution ++ +++ ++
Tracking of clonotypes +++ ++ +
Clinical use (e.g., MRD detection) ++ +/- -
Unbiased detection of unproductive rearrangements ++ - -
Inference of germline ++ + +/-
Determination of constant gene - ++ +
Structural annotation +/- ++ +
Linkage of both antigen receptor chains +/- +/- ++
Direct combination of AIRR-seq with single-cell
immunophenotype
(e.g., transcriptome or cell surface protein expression)
- - ++
Characterization of clonotype full antigen receptor/Functional
testing
- +/- ++
Rare clonotype detection ++ ++ +/-
Methods Simplicity of workflow (library preparation) +++ ++ +
Cost for library preparation commercial kits
(per sample)
Low Moderate High
Fidelity in sequences Moderate High High
Molecular barcoding (correcting PCR/sequencing error) +/- ++ ++
Potential
Issues
V-gene amplification bias ++ + +/-
V-gene annotation issues ++ + +
PCR and sequencing error ++ + +/-
Difficulty with translation of copy number to cells +/- ++ +/-
Degradation of template + ++ ++
bp = base pairs; CDR3 = complementarity determining region 3; MRD = minimal residual disease; RACE = rapid amplification of cDNA ends;
V = variable.
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prioritize their development, a written survey was developed asking participants about the use of
and need for controls for AIRR-seq experiments. The survey gathered information on participants’
research interests, sample types, sequencing methodologies, currently available controls, and
desired controls. In addition to the survey results, different AIRR-seq methods and controls were
also gleaned from the literature, and finally, the WG also invited scientists with unpublished research
on controls for their input. These three sources of data were then used to provide a comprehensive
overview of sequencing methods, technical issues, current standards, and potential priorities for the
development of future standards. Here we describe the progress of the Biological Resources WG of
the AIRR Community, its information collection and proposed strategies to define, develop, and use
AIRR-seq standards.
Biological controls in AIRR-seq experiments
AIRR Community survey: Overview and respondent demographics
To address the use, needs, and requirements for AIRR-seq controls and standards, we designed and
disseminated a questionnaire to researchers in the AIRR Community, as well as to users of IMGT, the
international ImMunoGeneTics information system (http://www.imgt.org) (Lefranc, 2014). The ques-
tionnaire was composed of 4 sections and included 28 questions, with tick-box predefined answers
and free-text options allowing for participants’ personalized answers (Supplementary material).
After 6 months, 105 responses were recorded, including one incomplete response from a participant
who neither produces nor analyzes AIRR-seq data. Three respondents participated twice, with con-
sistent answers and same name and contact information, therefore only one completed form was
considered for each. Answers from 101 remaining participants originated mainly from North America
and Europe (Figure 1A) and were further analyzed. At the time of the survey, 96% of respondents
were involved in AIRR-seq studies and 4% had plans to perform AIRR-seq studies in the future. Of
the respondents, 92% were engaged in human studies, 48% in mouse studies, and 38% in the use of
AIRR-seq to study other species or synthetic molecules (e.g., from phage-displayed antibody librar-
ies; Figure 1B). Approximately half of the respondents focused exclusively on IG while a quarter
each studied TR and IG or TR alone (Figure 1C). Several respondents were interested in many differ-
ent topics (Figure 1D and Figure 1—figure supplement 1), with their fields of interest dominated
by ‘immune system diseases’ including infection, autoimmune disease, and cancer. Furthermore, the
survey results clearly indicate an interest among the majority of respondents in developing bioinfor-
matic tools for the analysis of AIRR-seq data, followed by major interests in other research areas
such as vaccinology, immune repertoire homeostasis, immunotherapy, antibody engineering, hema-
tology, and aging (Figure 1D). In addition, respondents with bioinformatic skills tended to be those
who had broader research interests (Figure 1—figure supplement 1). Finally, 89/101 of survey
respondents indicated an interest in using AIRR-seq to either track clonotypes over time or across
samples, whereas 88/101 were interested in identifying highly expanded clonotypes, 87/101 on ana-
lyzing diversity, and 83/101 on studying clonal selection. In conclusion, participants in this survey
came from diverse backgrounds, had wet and dry bench expertise, and had a breadth of research
interests covering different aspects of AIRR-seq studies.
Survey results on sequencing methodologies used
Whereas 91% (92/101) questionnaire respondents commonly perform bulk sequencing experiments,
67% (68/101) combine bulk sequencing with the use of single-cell technologies. Only 8% of respond-
ents focused exclusively on single-cell sequencing or phage display technologies only. With respect
to the input biological material used in bulk sequencing, the majority of participants (83%) preferred
to sequence long amplicons that covered the entire (or almost the entire) V-(D)-J region and part of
the C region despite the associated higher sequencing cost per read and restrictions on the type of
compatible sequencer. AIRR-seq researchers mainly used mRNA for cDNA sequencing (69%), while
both mRNA and gDNA were used by 25%, and gDNA alone by 6% of respondents. Figure 2A
shows that the majority of survey respondents performing bulk sequencing used multiplex PCR or
the template-switching approach with a considerable number of AIRR-seq researchers using both
methods. For those using either approach, mRNA was still the preferred starting material. In addi-
tion, UMIs were more commonly used with template switching than multiplex PCR approaches
(Figure 2B). The association of UMIs with template switching methods is likely related to the
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template choice, since UMIs are not easy to use with gDNA-based templates, due to the incorpo-
ration of the UMI into the amplified products; nevertheless, two participants in the survey reported
using UMIs with gDNA (Figure 2B).
Altogether, these initial results suggest that among survey respondents bulk sequencing on
mRNA and gDNA are the most frequently used methods. However, the literature reflects increasing
use of single-cell approaches, including the computational construction of IG or TR from RNA-
sequencing (RNA-seq) libraries (Figure 2—figure supplement 1) and the combined use of target
capture plus single-cell RNA-seq (e.g., 10X Genomics’ 50 end kits, etc.).
To gain insight into which standards should be prioritized for development and sharing with the
scientific community, we asked survey participants about the standards they currently use and about
the types of standards they would like to use. Based on the results, we concentrate below on poten-
tial controls for bulk analysis, as this approach is being used by the majority of the respondents
(91%) and because the development of standards for single-cell applications is somewhat distinct.
Survey results on controls used and desired controls
Most respondents (88%) were interested in using standards or controls in AIRR-seq experiments.
The 47 respondents who already use controls (n = 47) did so for protocol development (12/
47 = 26%), everyday use (7/47 = 15%), or for both (15/47 = 32%), with the remaining (13/47 = 28%)
not indicating their specific application. Commercial controls were used by 11, and homebrew
Figure 1. Geographic distribution of survey participants and their AIRR-seq research interests. (A) Map with geographic distribution of survey
participants. (B) Histogram showing the principal studied organisms among the participants. The ‘Other’ category includes rat, ferret, rabbit, goat, pig,
canine, bovis, cattle, chicken, fish, teleost, salmon, zebrafish, other fish species, transgenic animals. (C) Venn diagram representing the percentage of
participants according to their interest in AIRR template type. (D) Pie-chart representing the distribution of survey participants according to their
research interest(s). Immune system diseases and other categories are described in more detail in the bar plots (right and left). Numbers of respondents
for each category are shown next to the bars.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Heatmaps of the areas of study depending on the interest.
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controls were used by 23 participants, with 3 people using both and 16 not specifying their source.
Figure 3A indicates that the most commonly used homebrew controls were cell lines or pooled-cell
preparations. Respondents who did not use controls (black bars) were also asked how they might
want to use controls. Figure 3B depicts the community survey responses to these questions.
In summary, the survey, as well as further discussions within the AIRR Biological Resources WG,
identified major concerns arising from different steps in the AIRR-seq workflow (Table 2, left and
middle columns). Additionally, based on these identified issues, the right column of Table 2
describes potential controls to address them. These controls are described in more detail in the sub-
sequent sections of the manuscript.
Current concepts in the use of biological standards for RNA-seq
experiments
To prioritize the development of community-wide standards for AIRR data, we turned to examples
of community-wide standards in the NGS space. Several such standards have been developed and
are actively used, for example, the External RNA Control Consortium (ERCC) spike-in controls and
the Microarray Quality Control (MAQC) RNA standards. Both of these standards were generated
through broad collaborations of stakeholders including the United States government, industry, and
academic researchers (Reid and External RNA Controls Consortium, 2005; Su et al., 2014).
The ERCC spike-in controls were designed specifically to be used with RNA-seq experiments, for
normalization of expression values during analysis. Two tubes with different compositions of the
RNA sequences are commercially available from Thermo Fisher Scientific as Invitrogen ERCC RNA
Spike-In Mix (https://perma.cc/WW9Z-D2NY) and ready for use with eukaryotic samples. Each tube
contains 92 RNA species with each containing a predefined polyA tail with a different sequence,
with their relative abundance covering a ~106 fold range, and a limited range of GC content and
lengths. The external RNA mixture can be used to normalize relative quantities of transcripts across
samples within a single experiment or project, and to optimize protocols for reproducibility and
accuracy. The ERCC standards are widely accepted by the transcriptome community, but do suffer
from a few limitations: (i) the GC content and range of lengths are not broad - representing the aver-
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Figure 2. Molecular approaches used in bulk sequencing. (A) Venn diagram representing the most important molecular approaches used and their
usage and sharing among participants. Numbers of respondents in each of the four main categories are shown in parentheses. (B) Bar plots
representing biological material used and molecular barcoding proportion for the two major molecular biology approaches (multiplex PCR and
template switching). Only the answers of respondents who used one technology exclusively are shown (Multiplex PCR: n = 29; Template switching:
n = 10). UMI = unique molecular identifier.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Yearly number of PubMed entries referring to single-cell AIRR sequencing (left panel) and bioinformatic AIRR reconstruction
from RNA-seq studies (right panel) 1980–2020 (via https://www.ncbi.nlm.nih.gov/pubmed/, accessed on 16 January 2020).
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Figure 3. Homebrew controls and their desired applications. (A) Most frequently used homebrew controls (total n = 47). (B) Total frequencies of
desired applications of homebrew controls for respondents currently using (gray bars; total n = 47) and currently not using controls (black bars; total
n = 42).
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and (iii) no splicing variants are included (Jiang et al., 2011). These limitations result from the typical
compromise accompanying any process for generating useful (and well validated) controls in a timely
fashion.
The MAQC RNA standards were not generated as NGS controls initially, but instead were devel-
oped by the U.S. Food and Drug Administration (FDA)-led, community-wide consortium for the pur-
pose of validating microarrays, instruments, and analysis methods. The MAQC project consists of
four phases, with the first two focusing on microarray methods and the second two on NGS methods
(SEQC; Sequencing QC). Initially, differential gene expression levels of nearly 1000 genes between
two human reference RNA samples (Human Brain RNA and Human Universal RNA) were assessed by
qRT-PCR and microarrays; these highly characterized RNA samples were subsequently used to vali-
date different microarray or NGS library preparation methods, instruments, and data analysis meth-
ods (Shi et al., 2006). Phase 3 of the MAQC project applied similar concepts to NGS platforms and
the comparison of results obtained by microarray or RNA sequencing (Su et al., 2014). Phase 4 of
this project is ongoing, with the goal of developing robust analysis protocols and providing quality
control metrics.
In addition, UMIs and unique dual indices (UDIs) have been proposed in the RNA-seq field
(https://perma.cc/AMB4-WC86) (Kircher et al., 2012) to control and correct for sequencing errors,
as well as sequencing index crosstalk.
Current practices for controls in AIRR-seq experiments
While the standards described above cannot be directly applied to AIRR-seq experimentation, they
can serve as a blueprint for the development of standards. In Table 2 (right column), we highlight
different possible approaches to address the concerns of the AIRR Community. These approaches
closely resemble the general standards described above, using spike-in controls or well-character-
ized biological samples, including UMIs or UDIs. As described below, AIRR-seq researchers have
already initiated some studies to address the use of such controls.
Several groups have recently developed synthetic standards for use with AIRR-seq samples of
mouse and human origin, all based on common principles, and generally available for academic
Table 2. Concerns and expected errors introduced during AIRR-seq workflows and possible controls to detect them.
A typical workflow consists of 5 steps: Sample collection > Extraction > Amplification > Sequencing > Analysis.
Concern Mechanism(s) Example of potential controls
Sequence errors Enzyme errors (RT, DNA polymerase); Sequencing errors UMIs for bioinformatic error correction;
Spike-in controls with defined sequences to evaluate error rates
Sensitivity Enzymatic inefficiencies (RT or PCR conditions/polymerase);
Sample collection size (e.g., cell input number, purity);
Sequencing depth
Spike-in controls (synthetic or cellular) at known concentrations
Specificity Enzyme bias (RT, DNA polymerase); Analysis pipelines
(annotation, error correction)




Bench-level cross contamination (sample mixing or PCR
contamination) or barcode jumping during sequencing




Sample collection or nucleic acid purification Identified by spectroscopy or agarose electrophoresis
Evaluate batch
effects





Enzymatic inefficiencies (RT or PCR conditions); Analytical
error correction
Spike-in controls (synthetic or cellular) at known concentrations
Reproducibility/
Batch effects
All stages Spike-in controls (synthetic or cellular); Parallel biological (clonal or
complex) sample; Comparison of replicate amplifications of the
same sample; Comparison of sequences generated on the same
sample in different sequencing runs
Data processing Database/annotation limitations; filtering; error correction;
collapsing/consensus algorithms
Spike-in controls (synthetic or cellular); Parallel biological (clonal or
complex) sample
RT, reverse transcriptase; UMIs, unique molecular identifiers; UDIs, unique dual indices.
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institutions via a material transfer agreement. These synthetic templates are either generated from
plasmids (via in vitro transcription followed by RT-PCR) or directly produced as synthetic dsDNAs,
with numbers of unique sequences produced ranging from dozens to over 1 million (Khan et al.,
2016; Friedensohn et al., 2018; Carlson et al., 2013) (and unpublished work of J. Trück, University
Children’s Hospital Zurich and C. Tipton, Emory University).
The first use of a synthetic repertoire was reported by Carlson et al., 2013. They developed syn-
thetic DNA templates combining 14 and 4 different V and J genes of the TR gamma (TRG) locus,
resulting in a total of 56 templates of equal length. All sequences contained three barcodes to
unambiguously identify individual V-J combinations. In addition, universal primer sites that were
identical in all synthetic templates were added on both ends. This approach allowed identification of
amplification bias and optimization of primer concentrations as well as informing the computational
correction of residual bias. Work on both murine and human IG repertoire was performed by
Khan et al., 2016 and Friedensohn et al., 2018 using a similar strategy in the same research labora-
tory. There, a total of 16 murine and 85 human synthetic sequences were used to assess primer bias
from multiplex PCR library generation. In combination with incorporation of UMIs into amplicons
and an error correction analysis pipeline, this approach increased workflow fidelity and produced
more accurate data. A very important element in the strategy used in this process was the integra-
tion of UMI during initial reverse transcription, resulting in labeling of each cDNA on a single mole-
cule level. In contrast to the study by Carlson et al., synthetic sequences used in both studies from
Khan et al. and Friedensohn et al. contained different CDR3 sequences and were used in different
relative concentrations within the spike-in pool. This approach allowed to not only assess primer-
dependent amplification bias but also the impact of variable input concentrations of synthetic
sequences on their relative abundance following sequencing.
In principle, synthetic templates are designed such that each mimics an individual recombined
V-(D)-J region and a partial C region while also containing universal priming sites, barcodes for
unique template identification. The universal priming sites allow for unbiased quantification. Further-
more, comparison of amplification efficiency with the universal vs. targeted primers (the latter usually
binding to the leader or V and J or C regions) may be used to correct for target-specific differences
in amplification efficiency. Through amplification of synthetic templates alone, multiplex primer sets
can be tuned to individual concentrations that will more accurately amplify known targets within rep-
ertoires or they can be used to eliminate primers that perform poorly altogether. Through the use of
known templated sequences of known abundance (e.g., cell lines spiked into other cells), quantifica-
tion and amplification efficiency can be calculated. Experience from early testing has identified cer-
tain limitations of this approach (see below). Some standards additionally harbor mutations
deviating from the germline (unmutated) IGHV sequences; these can be used to model the efficiency
of amplification of somatically mutated templates (Friedensohn et al., 2018). In practical terms, syn-
thetic standards can be used during method development (primer optimization, alteration of meth-
ods to account for amplification bias, etc.), as spike-ins, or can be run as separate positive controls
alongside the samples of interest. Synthetic templates can also serve as spike-in controls for concur-
rent quantification measurements of run-to-run variability, amplification and sequencing efficiency,
as a positive control, or as a measurement of sample-to-sample contamination and/or index of mis-
identification (using different synthetic library spike-ins for individual amplifications in a pooled
sequencing run).
Although theoretically promising, the molecular design and bioinformatic analyses of synthetic
sequences are challenging. Controls should mimic biological repertoires as closely as possible, and
therefore are most effective when they contain a representative level of the biological diversity,
which is tedious and expensive. In addition, they should also be distinguishable from other biological
sequences so that even following nucleotide changes introduced through PCR or sequencing errors,
such synthetic sequences can be unambiguously resolved from their biological counterparts. These
challenges may explain the rare usage of spike-in controls except for initial method optimization or
very specific applications.
Mixed-cell populations and cell lines can also be used as workflow controls, as has been docu-
mented recently by the Euroclonality Consortium (Knecht et al., 2019; Brüggemann et al., 2019).
The first type of Euroclonality (Knecht et al., 2019) control monitors general primer and sequencing
performance of a sequencing run (batch of samples) and consists of a poly-target control, comprised
of gDNA isolated from healthy human thymus, tonsil, and peripheral blood mononuclear cells
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(PBMCs), the latter derived from apheresis donors (in a 1:1:1 ratio). This control is included in the
workflow alongside experimental samples in a separate tube. By bioinformatic identification of the
primer sequences and comparison to stored reference sequencing profiles from the sample control
mix, unusual amplification patterns or batch effects can be identified. One advantage of such a cell
mixture control is that it fully models the immune repertoire complexity of a bulk cell population and
provides quality monitoring for every step of the process including amplification of the template and
its sequencing. A second advantage is that this type of control is very easy to generate and is there-
fore accessible to many laboratories. A disadvantage of using this type of complex control is that
one does not fully know the identity of all of the rearrangements in the sample, which can be prob-
lematic if there is sample or PCR contamination. A second disadvantage is that it is generated in a
finite amount - and once used up, the process of validating the control must be repeated.
The second type of control used by the Euroclonality Consortium (Brüggemann et al., 2019) is
designed to evaluate assay sensitivity and linearity within each library. This in-parallel control consists
of a gDNA sample obtained from 59 human B/T lymphoid cell lines with a total of 46 well-defined
rearrangements mixed together in different ratios and added to each processed sample. An advan-
tage of using cell lines as in-parallel controls is that their gene rearrangements are defined and thus
easily identified; theoretically allowing for the conversion of reads into cell numbers and permitting
relative quantification of template abundance. In practice, however, the use of in-parallel amplifica-
tion controls can be very challenging, and requires careful interpretation. For example, in samples
with poor gDNA quality or low template abundance, the control templates may outcompete the
test sample. The depth of sequencing and relative amounts of sample input can affect the measured
abundance (Barennes et al., 2021; Chaara et al., 2018). An additional disadvantage is that cell lines
do not model a fully diverse repertoire, only a fraction of V and J gene combinations are repre-
sented by the cell lines, and thus primer performance and bias, especially between samples, are not
fully controlled.
Discussion and future work
AIRR-seq experiments are becoming increasingly commonplace, in both the research and clinical set-
tings. In contrast, the development of controls and best practices for assay validation, interpretation
and standardization have lagged behind. Here, the members of the AIRR Community Biological
Resources WG have summarized the current practice regarding the use of standards and controls
among its members as well as among other international AIRR-seq experts and in the literature. We
also have identified differences in the types of standards and controls that are used among users.
Some of these differences depend on the sample type (fresh vs. fixed cells), the starting material
(single cell vs. bulk), the template (mRNA vs. gDNA), as well as the quality and quantity of the rele-
vant cells and templates. In addition, the selection of controls is influenced by the amplification
method, with single cell and mRNA-based methods relying more heavily on cellular and molecular
barcoding approaches, for example. Last, but certainly not least, the downstream application of the
assay can profoundly influence the choice and prioritization of controls. In some cases, assays need
to be sensitive and specific (e.g., a clinical grade assay that detects minimal residual disease)
whereas in others quantitation (e.g., clonal size analysis for monitoring clonal expansions) or unbi-
ased amplification (e.g., assessment of repertoire skewing during an immune response) may be
more important.
All AIRR-seq assays can clearly benefit from rigorous controls. There is broad agreement that con-
trols and standards are desirable, with over half of AIRR-seq survey respondents currently already
using controls (mostly of a homebrew variety) in their experiments. Furthermore, whether individuals
used controls or did not, they appeared to agree on the types of issues in analyzing and interpreting
AIRR-seq data that would benefit from the use of controls - most importantly measuring and control-
ling for sample quality, assay sensitivity and specificity, and calibration for the quantification of clonal
size. Also, with the progress regarding antigen-specificity inference using computational tools
(Glanville et al., 2017; Huang et al., 2020; Jokinen et al., 2021; Akbar et al., 2021;
Hayashi et al., 2021; Richardson et al., 2021; Galson et al., 2015; Shomuradova et al., 2020;
Chronister et al., 2021; Sidhom et al., 2021; Pogorelyy et al., 2019; Dash et al., 2017) or more
conventionally through technologically challenging using antigen-binding approaches, including sin-
gle-cell (Johnson et al., 2020; Fuchs et al., 2019), having controls would be of major interest to
ensure the accuracy of the TR or IG identified. It is unlikely that a single control can fulfill all of these
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needs across all methods and applications. There is at the moment also no obvious front-runner for
a ‘gold standard’ that can be used to judge the adequacy of different types of controls.
Having identified a need, a diversity of methodologic approaches and the lack of a ‘gold stan-
dard’ for AIRR-seq controls, the AIRR Community Biological Resources WG is now coordinating the
development of such controls. Although AIRR-seq researchers are aware of potential methodological
problems, current solutions have not been systematically evaluated or compared. Based upon the
current use of controls and needs identified by our survey respondents, the WG plans to focus on
three forms of controls: one in-parallel (synthetic standards), one in-parallel and computational
(UMIs), and one that is external (a complex cell mixture that is run in parallel to monitor amplification
and sequencing run batch effects). To optimize these three types of standards, we first must deter-
mine how well they work. We therefore propose to carry out a multi-center analysis of three types of
controls: (1) synthetic calibrators for bulk gDNA sequencing to measure clonal size and amplification
bias; (2) UMIs for samples studied in parallel by bulk mRNA (with UMIs) and single cell sequencing
(with cellular barcodes) for the analysis of amplification bias and sequencing error; and (3) a mixed
cell population (either a human apheresis and/or pooled tissue product or murine spleen samples)
for the evaluation of batch effects that compare between sequencing runs performed at the same
site or between runs performed at different sites. These three types of controls can be run in parallel
or in separate, dedicated experiments, allowing for greater participation of AIRR-seq investigators.
In order to perform these studies, the Biological Resources WG will first establish a framework
suited to the analysis and quantitation of potential issues, depending on the type and amount of
input material, the assay(s) used, and the analysis method(s). Since the method used for the produc-
tion of AIRR-seq data can impact the results, as shown by the benchmarking of TR library prepara-
tion methods study (Barennes et al., 2021), we plan to evaluate different standards in the
framework of a molecular biology method benchmarking study as well. For the TR repertoire, we
will take advantage of the already evaluated methods to include more gDNA-based methods. For
the IG repertoire analysis, we will launch a systematic study, leveraging high-volume pooled-cell col-
lections and synthetic standards that can be shared by investigators at multiple sites. We plan four
major experiments: (1) analysis of TR and IG rearrangements in PBMCs using bulk gDNA and RNA
approaches; (2) analysis of TR on sorted naı̈ve polyclonal T cells using bulk gDNA; (3) analysis of IG
rearrangements on sorted naı̈ve polyclonal B cells using bulk gDNA and RNA; and (4) analysis of IG
rearrangements on spleen cells from organ donors using bulk gDNA and RNA approaches. Spleen
cells are enriched for memory B-cell clones and are useful for modeling clonal expansion and somatic
hypermutation (Meng et al., 2017). Synthetic controls and UMIs (in the case of RNA-based sequenc-
ing) will be added to triplicate samples of PBMCs and polyclonal splenocytes. Samples will be run
with and without spike-in controls that will be included at different ratios. Ideally, the selected meth-
ods will all be handle by 2 to 3 labs, a compromise between feasibility and inter-lab validation. Pro-
tocols and workflows will be standardized and shared. To avoid sequencing batch effect, we will
sequence all the replicates through the same facility. Based on the results and to determine the low-
est possible cell input levels, we will then evaluate the impact of decreasing the quantity of cells and
repeat the same schema, focusing on the most reproducible methods. Finally, we will work closely
with other AIRR Community working groups and additional experts in the field to harmonize stan-
dardization efforts. Together with the AIRR Community Software WG, we will select a series of tools
for data quality control, alignment, and annotation and identify the analysis pipelines required for
the detection of contamination, amplification bias, and batch effects. By leveraging the diverse skills
of AIRR Community investigators, the development, optimization, and dissemination of biological
standards for AIRR-seq data should progress quickly. Such ambitious project will require financial
support in order to help volunteer labs to handle the experiments, already under discussion at the
level of the AIRR-community.
Using, testing, and comparing these standards is but the first step. Beyond that is their adoption
by the wider scientific community. For widespread adoption, commercial and other partnerships are
essential for high-quality production and dissemination of the standards. In addition, to ensure
broad distribution, controls should either be free of significant intellectual property restrictions or, if
proprietary, be well-documented. For this, the Biological Resources WG will reach out to academic
research groups (e.g., IMGT), non-profit organizations (e.g., the Global Alliance for Genomics and
Health), governmental organizations (e.g., the US Department of Commerce’s National Institute of
Standards and Technology), as well as commercial entities (e.g., the ATCC). With these efforts, we
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will be able to improve the rigor, robustness and interchangeability of AIRR-seq studies, and to
increase their utility for downstream applications, including clinical diagnostics.
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